Financial Performance - The company's operating revenue for Q1 2023 was CNY 286,560,377.99, a decrease of 5.10% compared to CNY 301,958,988.82 in the same period last year[4] - Net profit attributable to shareholders was CNY 19,349,332.43, down 73.91% from CNY 74,168,573.48 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 15,561,733.77, a decrease of 79.32% compared to CNY 75,262,091.90 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.22, a decrease of 73.81% from CNY 0.84 in the previous year[4] - Net profit for the period was CNY 22,867,144.85, down 74.0% from CNY 87,958,734.62 in Q1 2022[19] - The net profit for Q1 2023 was CNY 19,349,332.43, a significant improvement compared to a net loss of CNY 74,168,573.48 in the same period last year, representing a turnaround of approximately 126%[20] - The company reported a decrease in sales revenue from CNY 313,334,689.40 in Q1 2022 to CNY 283,170,181.44 in Q1 2023, a decline of about 9.6%[21] Cash Flow and Assets - The net cash flow from operating activities was CNY 58,337,902.67, down 43.53% from CNY 103,314,893.79 in the same period last year[4] - Cash and cash equivalents at the end of the quarter were CNY 485,537,595.56, a decrease from CNY 515,449,608.39 at the beginning of the year[18] - Total cash and cash equivalents at the end of Q1 2023 were CNY 484,149,429.77, down from CNY 628,417,660.68 at the end of Q1 2022, a decrease of about 22.9%[23] - Operating cash inflow for Q1 2023 was CNY 287,111,040.43, down from CNY 316,066,571.72 in Q1 2022, reflecting a decrease of about 9.2%[21] - The company invested CNY 97,838,674.51 in fixed assets and intangible assets during Q1 2023, compared to CNY 52,486,090.96 in Q1 2022, representing an increase of approximately 86.2%[22] Expenses and Liabilities - Total operating costs increased to CNY 262,441,239.37, up 22.5% from CNY 214,113,341.19 in Q1 2022[19] - Sales expenses rose by 40.64% to CNY 133,965,927.69, primarily due to increased employee compensation and meeting costs[9] - Total liabilities rose to CNY 250,015,468.98, up from CNY 230,634,015.20 at the beginning of the year[18] - The company reported a significant increase in contract liabilities to CNY 10,207,350.65, compared to CNY 2,005,290.19 in the previous period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,961, with the largest shareholder, Liu Jidong, holding 28.59% of shares[11] - Liu Jidong holds 25,315,500 shares, with 18,986,625 shares under lock-up conditions and 3,530,000 shares pledged[11] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder holding 4.35%[11] - The company’s major shareholders do not hold shares through margin trading accounts[12] Research and Development - The company increased its R&D expenditure compared to the previous year, contributing to the decline in net profit[7] - Research and development expenses rose to CNY 28,684,039.18, an increase of 28.5% compared to CNY 22,312,058.34 in the previous year[19] - The company is actively expanding its product offerings and enhancing its technological capabilities through various certifications and approvals[16] Government Support and Certifications - The company reported a significant increase in government subsidies, with other income rising by 423.87% to CNY 5,064,032.46[9] - The company’s technology center has been recognized as a national enterprise technology center, eligible for tax benefits and policy support[14] - The subsidiary, Shenyang Xingqi Eye Hospital, has been certified as a high-tech enterprise, enjoying a reduced corporate income tax rate of 15% for three years[15] - The company’s product, Compound Electrolyte Eye Wash, has been included in the National Medical Insurance Directory[16] - The company has received a drug registration certificate for Sodium Hyaluronate Eye Drops, with approval number H20233348[16] - The company signed a project investment agreement with the Shenyang Free Trade Zone Management Committee, indicating ongoing investment activities[13] Audit Status - The company has not undergone an audit for the Q1 2023 report[24]

Financial Performance - The company reported a total revenue of CNY 1.2 billion for the fiscal year 2022, representing a year-on-year growth of 15%[29]. - The net profit attributable to shareholders was CNY 300 million, an increase of 20% compared to the previous year[29]. - The company's operating revenue for 2022 was CNY 1,249,855,370.83, representing a 21.59% increase compared to CNY 1,027,914,866.71 in 2021[34]. - The net profit attributable to shareholders for 2022 was CNY 211,684,305.31, an increase of 8.72% from CNY 194,702,374.35 in 2021[34]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[29]. - The company anticipates a revenue guidance of CNY 1.5 billion for 2023, representing a growth target of 25%[29]. - The total profit for the year was ¥233,718,204.58, which decreased by 4.03% year-on-year[56]. - The company achieved quarterly revenues of CNY 301,958,988.82 in Q1, CNY 298,613,531.46 in Q2, CNY 403,699,656.59 in Q3, and CNY 245,583,193.96 in Q4 of 2022[36]. Research and Development - The company is committed to improving its R&D capabilities and expanding its product pipeline to address risks related to unmet expectations in R&D projects[10]. - Research and development expenses accounted for 12% of total revenue, reflecting the company's commitment to innovation[29]. - The company intends to broaden its ophthalmic product line and increase R&D investments to stay competitive in a rapidly evolving market[8]. - The company’s R&D efforts led to the approval of new drug specifications for Moxifloxacin eye drops and the initiation of clinical trials for Voriconazole eye drops[62]. - The company is developing new drugs for retinal diseases, including SQ-21127 and SQ-129, which are in the preclinical research stage[85]. - The total R&D investment for 2022 was ¥190,199,971.05, accounting for 15.22% of operating revenue, up from 11.47% in 2021[86]. - The number of R&D personnel increased by 11.05% to 191, with a significant rise in master's degree holders by 66.15%[86]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, projecting a revenue contribution of CNY 200 million from this region by 2024[29]. - The company is aware of the intensified internal competition within the pharmaceutical industry and will seek to explore new markets to sustain growth[9]. - The company plans to launch three new ophthalmic products in 2023, targeting a market share increase of 10% in the next fiscal year[29]. - The company is exploring market expansion opportunities in Southeast Asia, aiming for a 30% increase in international sales by 2024[196]. - A strategic acquisition of a local competitor is expected to enhance the company's product portfolio and increase market penetration by 15%[29]. Operational Efficiency and Cost Management - The company will actively seek new suppliers and manage procurement costs to counteract the rising costs of raw materials and ensure production efficiency[11]. - The company has implemented new technologies in production, which are expected to reduce costs by 5% in the next fiscal year[196]. - The company has established long-term stable relationships with suppliers for raw material procurement, ensuring quality and reliability[52]. - The production center will optimize production strategies to ensure sustained supply after products enter the medical insurance directory[111]. Corporate Governance and Management - The board of directors consists of 9 members, including 3 independent directors, complying with relevant laws and regulations[122]. - The supervisory board has 3 members, including 1 employee representative, meeting legal requirements[123]. - The company has established a strict internal control management system covering decision-making, asset management, procurement, and financial reporting[124]. - The company maintains independence from its controlling shareholders in business operations, personnel, assets, and financial matters[129][130][131][132][133]. - The company has a structured remuneration scheme approved by the shareholders' meeting[146]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 14.24 million[149]. Environmental Compliance and Social Responsibility - The company has implemented a wastewater treatment process using pre-treatment, A/O, and MBR methods, ensuring that all treated wastewater meets national and local regulatory standards[197]. - The company has invested a total of 2.1 million yuan in environmental protection in 2022, including 1.5 million yuan in environmental facilities and 400,000 yuan for hazardous waste disposal[199]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental bureau[197]. - The company collaborated with local welfare foundations to support 81 low-income disabled families in developing breeding projects, contributing to local economic improvement[200]. - The company has signed donation agreements to establish "Bright Future" funds aimed at enhancing rural education and infrastructure[200]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of 10 CNY per 10 shares to all shareholders, based on a total of 88,555,082 shares[16]. - The company reported a distributable profit of 494,976,789.61 RMB for the period[166]. - The cash dividend distribution plan is subject to approval at the company's 2022 annual general meeting and aligns with the company's articles of association regarding profit distribution[169]. - The independent directors confirmed that the profit distribution plan does not harm the interests of shareholders, especially minority shareholders[169]. - The company has a clear profit distribution policy that ensures the protection of shareholders' rights, particularly for minority shareholders[164].

为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 27 日（星期四）17：00 前访问 https://ir.p5w.net/zj/进入问题征集专题 页面进行提问。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进 行回答。 证券代码：300573 证券简称：兴齐眼药 公告编号：2023-016 沈阳兴齐眼药股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）《2022 年年度报告》及摘要 已于 2023 年 4 月 20 日在巨潮资讯网（http://www.cninfo.com.cn/）予以披露， 为让广大投资者能进一步了解公司 2022 年年度报告和 2022 年生产经营情况，公 司将于 2023 年 4 月 28 日（星期五）15:00-17:00 时举行 2022 年度业绩说明会。 本次业绩说明会将采用网络远程方式举行，投资者可登陆 ...

Group 1: Market Focus and Product Development - The global focus on retinal drugs and dry eye disease is increasing, with dry eye treatment evolving beyond just hydration to include inflammation control [2] - The market for dry eye disease is expected to grow significantly, with the approval of cyclosporine showing positive clinical results [2] - Companies are developing monoclonal antibodies and small molecule drugs for retinal diseases, indicating a diverse future market [3] Group 2: Product Launch and Strategy - The product "Zirun" received national approval in June 2020, with a dedicated team responsible for 500 hospitals for clinical data collection [3] - The 0.05% cyclosporine has entered the preliminary medical insurance directory [3] Group 3: Research and Collaboration - The company is collaborating with foreign research institutions to develop small molecule anti-VEGF drugs [3] - There is a focus on developing innovative products in the field of ophthalmic devices, with plans to advance from third-generation to fourth-generation OK lenses [3] Group 4: Clinical Trials and Regulatory Compliance - The company aims to complete the enrollment for low-concentration atropine clinical trials by the end of 2020, with results expected in 2023-2024 [4] - The clinical trials for new indications must comply with national regulations, similar to new drug applications [4] Group 5: Market Competition and Challenges - There is currently no administrative protection period for low-concentration atropine, but data protection exists [4] - Other companies' formulations for preventing myopia in adolescents cannot be authorized if they are for the same indication [4]

Company Overview - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. focuses on the research, production, and sales of ophthalmic drugs, primarily prescription medications [2][3]. - The company was established in July 2000 and was listed on the Shenzhen Stock Exchange in December 2016, with the stock code 300573 [4]. Financial Performance - In 2017, the company achieved a revenue of ¥360,006,690.25, representing a year-on-year growth of 6.17% [3]. - The revenue composition includes: - Gel/eye ointment: ¥232,801,419.44 (64.67% of total revenue, up 4.61% YoY) - Eye drops: ¥114,042,238.23 (31.68% of total revenue, up 10.71% YoY) - Solution: ¥12,319,145.16 (3.42% of total revenue) - Other products: ¥843,887.42 (0.23% of total revenue) [3]. Research and Development - The R&D investment in 2017 was ¥31,837,000, accounting for 8.84% of total revenue, an increase of ¥12,251,500 from 2016 [4]. Market Strategy - The company plans to enhance its marketing efforts by increasing the number of first-level distributors and improving academic promotion personnel training [4]. - The strategy includes expanding coverage to more medical institutions and conducting various academic activities to boost product market share [4]. Product Development - The company’s cyclosporine eye drops are included in the priority review process, aimed at treating dry eye syndrome [5]. - The Xiamen Daka project is currently in the preclinical research stage, focusing on tissue-engineered corneas [5].